Appln. No. 10/536,963 Response dated December 11, 2006 Reply to Office action of October 11, 2006

REMARKS

The examiner considers this application to contain two inventions or groups of inventions (I-II) which are not so linked as to form a single general inventive concept under PCT Ruler 13.1.

Applicants elect without traverse the invention of Group II, claims 8-17, drawn to a method for ameliorating neurotransmission dysfunction disease by administering a medicament comprising selenocysteine-containing protein.

Furthermore, in response to the election of species of a neurotransmission dysfunction disease and a peptide sequence, applicants elect without traverse the species of (a) Myasthenia gravis for a neurotransmission dysfunction disease and the species of (m) SEQ ID NO:4 for the peptide sequence.

It is understood that, upon allowance of a generic claim, applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CDR 1.141.

Favorable consideration and allowance are respectfully solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

By /ACY/
Allen C. Yun
Registration No. 37,971

ACY:pp

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528

G:\BN\A\Aoyb\KAWAMURA69\pto\2006-12-11response.doc